BioCentury | Dec 13, 2019
Company News

Novartis gains CHMP support for Eylea competitor in wet AMD

...than standard-of-care Eylea aflibercept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in the Phase III HAWK and HARRIER...
BioCentury | Oct 8, 2019
Company News

Oct. 8 Company Quick Takes: Novartis’ anti-VEGF approved for AMD; plus Merck-4D, Acorda, Clinuvel and Puma

...AG (NYSE:NVS; SIX:NOVN) to treat wet age-related macular degeneration. In the Phase III HAWK and HARRIER...
BioCentury | Apr 15, 2019
Company News

FDA accepts BLA for Novartis' AMD therapy

...antibody fragment in the U.S. by year end. In both the Phase III HAWK and HARRIER...
BioCentury | Aug 17, 2018
Clinical News

FDA gives green light for Regeneron's 12-week Eylea regimen

...year for the next-generation single-chain anti-VEGF antibody fragment. In both the Phase III HAWK and HARRIER...
BioCentury | Aug 13, 2018
Company News

Delay for Regeneron’s 12-week Eylea regimen

...year for the next-generation single-chain anti-VEGF antibody fragment. In both the Phase III HAWK and HARRIER...
BioCentury | Nov 17, 2017
Clinical News

Novartis details brolucizumab wet AMD data

...briefing, Novartis AG (NYSE:NVS; SIX:NOVN) detailed secondary endpoint data from the Phase III HAWK and HARRIER...
...in best corrected visual acuity (BCVA) (see BioCentury, June 23 ). In both HAWK and HARRIER...
BioCentury | Nov 10, 2017
Clinical News

Novartis details brolucizumab wet AMD data

...Friday, Novartis AG (NYSE:NVS; SIX:NOVN) detailed secondary endpoint data from the Phase III HAWK and HARRIER...
...best corrected visual acuity (BCVA) (see BioCentury Extra, June 20) . In both HAWK and HARRIER...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...4Q17 Novartis AG (NYSE:NVS; SIX:NOVN) Brolucizumab Neovascular age-related macular degeneration Additional Ph III HAWK and HARRIER...
...In June, Novartis said brolucizumab met its primary endpoint in the Phase III HAWK and HARRIER...
BioCentury | Jun 23, 2017
Clinical News

Novartis' wet AMD therapy non-inferior to Eylea

...Novartis AG (NYSE:NVS; SIX:NOVN) reported data from the 96-week Phase III HAWK and HARRIER trials in...
...in BCVA over weeks 36-48. HAWK evaluated 3 and 6 mg doses of brolucizumab and HARRIER...
...to adjust to every 2 month dosing based on disease activity assessments. In HAWK and HARRIER...
BioCentury | Jun 20, 2017
Clinical News

Novartis' wet AMD therapy non-inferior to bi-monthly Eylea

...whose label recommends dosing every eight weeks. The primary endpoints of the 96-week HAWK and HARRIER...
...patients. Following a three-month loading period, 57% and 52% of brolucizumab patients in HAWK and HARRIER...
Items per page:
1 - 10 of 18
BioCentury | Dec 13, 2019
Company News

Novartis gains CHMP support for Eylea competitor in wet AMD

...than standard-of-care Eylea aflibercept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in the Phase III HAWK and HARRIER...
BioCentury | Oct 8, 2019
Company News

Oct. 8 Company Quick Takes: Novartis’ anti-VEGF approved for AMD; plus Merck-4D, Acorda, Clinuvel and Puma

...AG (NYSE:NVS; SIX:NOVN) to treat wet age-related macular degeneration. In the Phase III HAWK and HARRIER...
BioCentury | Apr 15, 2019
Company News

FDA accepts BLA for Novartis' AMD therapy

...antibody fragment in the U.S. by year end. In both the Phase III HAWK and HARRIER...
BioCentury | Aug 17, 2018
Clinical News

FDA gives green light for Regeneron's 12-week Eylea regimen

...year for the next-generation single-chain anti-VEGF antibody fragment. In both the Phase III HAWK and HARRIER...
BioCentury | Aug 13, 2018
Company News

Delay for Regeneron’s 12-week Eylea regimen

...year for the next-generation single-chain anti-VEGF antibody fragment. In both the Phase III HAWK and HARRIER...
BioCentury | Nov 17, 2017
Clinical News

Novartis details brolucizumab wet AMD data

...briefing, Novartis AG (NYSE:NVS; SIX:NOVN) detailed secondary endpoint data from the Phase III HAWK and HARRIER...
...in best corrected visual acuity (BCVA) (see BioCentury, June 23 ). In both HAWK and HARRIER...
BioCentury | Nov 10, 2017
Clinical News

Novartis details brolucizumab wet AMD data

...Friday, Novartis AG (NYSE:NVS; SIX:NOVN) detailed secondary endpoint data from the Phase III HAWK and HARRIER...
...best corrected visual acuity (BCVA) (see BioCentury Extra, June 20) . In both HAWK and HARRIER...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...4Q17 Novartis AG (NYSE:NVS; SIX:NOVN) Brolucizumab Neovascular age-related macular degeneration Additional Ph III HAWK and HARRIER...
...In June, Novartis said brolucizumab met its primary endpoint in the Phase III HAWK and HARRIER...
BioCentury | Jun 23, 2017
Clinical News

Novartis' wet AMD therapy non-inferior to Eylea

...Novartis AG (NYSE:NVS; SIX:NOVN) reported data from the 96-week Phase III HAWK and HARRIER trials in...
...in BCVA over weeks 36-48. HAWK evaluated 3 and 6 mg doses of brolucizumab and HARRIER...
...to adjust to every 2 month dosing based on disease activity assessments. In HAWK and HARRIER...
BioCentury | Jun 20, 2017
Clinical News

Novartis' wet AMD therapy non-inferior to bi-monthly Eylea

...whose label recommends dosing every eight weeks. The primary endpoints of the 96-week HAWK and HARRIER...
...patients. Following a three-month loading period, 57% and 52% of brolucizumab patients in HAWK and HARRIER...
Items per page:
1 - 10 of 18